Back surgeries dropped from 12.5% to 1.8%; Injection use plummeted from 81.7% to 18.8%; Patients reported up to 57% pain reduction, improved mobility, …
Source: back pain
A large risk-bearing provider in NJ cut MSK costs by 81%, saving $9M in 20 months, using Apos®—a non-invasive, foot-worn device for chronic knee …
Source: joint pain relief
JAMA Neurology study (2016) from Dr. Waxman's lab that used genomic analysis to guide successful treatment of erythromelalgia. "Neuropathic Pain".
Source: nerve pain medication
Of those, 616 chronic knee or back pain patients got Apos®, while 3,576 matched controls received standard musculoskeletal (MSK) care. Besides cost …
Source: back pain
